Ikena Oncology Inc. and Inmagene Biopharmaceuticals Appoint Kristin Yarema as CEO of Newly Merged ImageneBio

Reuters

2025/07/23

Ikena Oncology Inc. and Inmagene Biopharmaceuticals Appoint Kristin Yarema as CEO of Newly Merged ImageneBio

Ikena Oncology, Inc. and Inmagene Biopharmaceuticals have announced the appointment of Kristin Yarema, Ph.D., as the Chief Executive Officer of their newly merged company, ImageneBio, Inc. The merger is expected to close by the end of July 2025. Dr. Yarema brings extensive leadership experience in human therapeutics, having previously served as CEO of Poseida Therapeutics, Inc. The combined company will focus on developing treatments for autoimmune and inflammatory diseases and will trade on Nasdaq under the ticker symbol "IMA".

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ikena Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9499194-en) on July 23, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2553243863"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553243863\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2553243863?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-23 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553243863","market":"us","top_or_hot":-1,"title":"Ikena Oncology Inc. and Inmagene Biopharmaceuticals Appoint Kristin Yarema as CEO of Newly Merged ImageneBio","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ikena Oncology Inc. and Inmagene Biopharmaceuticals Appoint Kristin Yarema as CEO of Newly Merged ImageneBio\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IKNA\">Ikena Oncology, Inc.</a> and Inmagene Biopharmaceuticals have announced the appointment of Kristin Yarema, Ph.D., as the Chief Executive Officer of their newly merged company, ImageneBio, Inc. The merger is expected to close by the end of July 2025. Dr. Yarema brings extensive leadership experience in human therapeutics, having previously served as CEO of <a href=\"https://laohu8.com/S/PSTX\">Poseida Therapeutics, Inc.</a> The combined company will focus on developing treatments for autoimmune and inflammatory diseases and will trade on Nasdaq under the ticker symbol \"IMA\".\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ikena Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9499194-en) on July 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ikena Oncology Inc. and Inmagene Biopharmaceuticals Appoint Kristin Yarema as CEO of Newly Merged ImageneBio</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIkena Oncology Inc. and Inmagene Biopharmaceuticals Appoint Kristin Yarema as CEO of Newly Merged ImageneBio\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-23 21:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ikena Oncology Inc. and Inmagene Biopharmaceuticals Appoint Kristin Yarema as CEO of Newly Merged ImageneBio\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IKNA\">Ikena Oncology, Inc.</a> and Inmagene Biopharmaceuticals have announced the appointment of Kristin Yarema, Ph.D., as the Chief Executive Officer of their newly merged company, ImageneBio, Inc. The merger is expected to close by the end of July 2025. Dr. Yarema brings extensive leadership experience in human therapeutics, having previously served as CEO of <a href=\"https://laohu8.com/S/PSTX\">Poseida Therapeutics, Inc.</a> The combined company will focus on developing treatments for autoimmune and inflammatory diseases and will trade on Nasdaq under the ticker symbol \"IMA\".\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ikena Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9499194-en) on July 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250723:nNDL3p59kb:1","article_id":"2553243863","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553243863","pubTimestamp":1753275623,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ikena Oncology, Inc. and Inmagene Biopharmaceuticals have announced the appointment of Kristin Yarema, Ph.D., as the Chief Executive Officer of their newly merged company, ImageneBio, Inc. The merger is expected to close by the end of July 2025. Dr. Yarema brings extensive leadership experience in human therapeutics, having previously served as CEO of Poseida Therapeutics, Inc. The combined company will focus on developing treatments for autoimmune and inflammatory diseases and will trade on Nasdaq under the ticker symbol \"IMA\".Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ikena Oncology Inc. published the original content used to generate this news brief via GlobeNewswire  on July 23, 2025, and is solely responsible for the informat","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4588":"碎股","BK4539":"次新股","NDAQ":"纳斯达克OMX交易所","BK4585":"ETF&股票定投概念","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4112":"金融交易所和数据","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IMA":"ImageneBio, Inc.","IKNA":"Ikena Oncology, Inc.","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H"},"translate_title":"Ikena Oncology Inc.和Inmagene Biopharmaceuticals任命Kristin Yarema为新合并的ImageneBio首席执行官","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"IKNA":0.9,"IMA":0.9},"content_text":"Ikena Oncology Inc. and Inmagene Biopharmaceuticals Appoint Kristin Yarema as CEO of Newly Merged ImageneBio\n    \n\nIkena Oncology, Inc. and Inmagene Biopharmaceuticals have announced the appointment of Kristin Yarema, Ph.D., as the Chief Executive Officer of their newly merged company, ImageneBio, Inc. The merger is expected to close by the end of July 2025. Dr. Yarema brings extensive leadership experience in human therapeutics, having previously served as CEO of Poseida Therapeutics, Inc. The combined company will focus on developing treatments for autoimmune and inflammatory diseases and will trade on Nasdaq under the ticker symbol \"IMA\".\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ikena Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9499194-en) on July 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}